SOURCE: Industrial Biotechnology Corp.

January 10, 2007 13:28 ET

Industrial Biotechnology Corporation Develops Nootkatone

SARASOTA, FL -- (MARKET WIRE) -- January 10, 2007 --Industrial Biotechnology Corporation (PINKSHEETS: IBTY) (IBC), a company dedicated to new biotechnologies and innovations in the chemical industry, today announced they have made Nootkatone through the use of the company's proprietary ALCHEMx Production Platforms™.

The ALCHEMx Production Platforms™ are the combination and integration of proprietary systems, intellectual property, licensed patents and the application of technologies which result in the conversion of inexpensive raw materials into useful products with high commercial values.

Utilizing proprietary processes, the company's biocatalysis platform creates special proteins, referred to as designer enzymes that transform low value materials into high value compounds, while its biosynthesis platform harnesses cells to convert simple raw materials into complex high value molecules.

As a result, IBC can custom design cytochrome P450 enzymes by modifying the enzymes' internal structure. The modified enzyme can then be used with a particular substrate to create a specifically desired product.

It is this technology that has enabled IBC to produce Nootkatone, most often recognized as the tangy clean scent of a grapefruit that is often found in soaps, disinfectants and other products.

However, producing that scent, which is derived from Nootkatone, requires extracting the oil of grapefruit from its peel, a process that's both time-consuming and expensive. IBC's technology enables it to produce Nootkatone at a fraction of the cost that has been incurred historically.

Nootkatone is only the first of some 40,000 commercially available biological chemical compounds that IBC can now design, develop and manufacture at significantly lower costs, with substantially lower environmental impact, than was possible with traditional manufacturing methodologies.

These chemical compounds are used in a wide range of industries including: flavors and fragrances, fine chemicals, pharmaceuticals, cosmeceuticals, agricultural, bio-pesticides, bio-energy, biomaterials and biopolymers.

Both of these platforms integrate patents and intellectual property previously licensed by IBC from Oxford University and Rice University, while at the same time applying proprietary processes, technologies and applications which include molecular and metabolomic engineering, fermentation, biotransformation, enzyme and protein engineering and product recovery.

About Industrial Biotechnology Corporation

Industrial Biotechnology Corporation (IBC) enables the biological production of chemicals through a combination of licensed patents, intellectual property and proprietary systems. We accomplish this through our ALCHEMx Productions Platforms™ which are a systematic, streamlined approach to biologically manufacture chemicals more efficiently, at significantly lower costs, and with substantially lower environmental impact than traditional methods. IBC and its partners plan to produce and market new and established biologically produced chemicals to the pharmaceutical, bio-energy, agricultural, biopesticides, fine chemicals, flavors and fragrances, cosmeceuticals, biomaterials and biopolymer industries. For more information about Industrial Biotechnology Corporation, please visit its website at

Forward-Looking Statements

Certain matters discussed in this press release are "forward-looking statements." These forward-looking statements can generally be identified as such because the context of the statement will include words such as "expects," "should," "believes," "anticipates" or words of similar import. Similarly, statements that describe Industrial Biotechnology Corporation's future plans, objectives or goals are also forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties, including the financial performance of Industrial Biotechnology Corporation, as appropriate, which could cause actual results to differ materially from those currently anticipated. Although Industrial Biotechnology Corporation believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, they cannot give any assurance that their expectations will be attained. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating any forward-looking statements. Certain factors could cause results and conditions to differ materially from those projected in these forward-looking statements, and some of these factors are discussed below. These factors are not exhaustive. New factors, risks and uncertainties may emerge from time to time that may affect the forward-looking statements made herein. These forward-looking statements are only made as of the date of this press release and Industrial Biotechnology Corporation does not undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Contact Information

  • Contact:
    Investor Relations
    Industrial Biotechnology Corporation
    2033 Main Street
    Sarasota, FL 34237
    Email Contact